Cypralis is a private limited liability company and is currently owned by its founder shareholders. Our strategy is to raise finance from venture capital, pharma collaborations and non-dilutive funding sources in order to achieve clinical proofs of concept in acute indications where novel PPIase-inhibitors may offer new breakthroughs for the treatment of serious hospital-based indications.

Please contact us to explore opportunities for collaboration or investment.

+44 (0)1277 367 020